Who Is Yuvan Thakkar, The First Indian-Origin Teen To Receive UK's Life-Changing Cancer Therapy?

Yuvan Thakkar, a teenager of Indian origin diagnosed with cancer, expresses profound gratitude for the life-altering treatment that has enabled him to embrace his passions.

This transformative therapy, made accessible through a fund established by the UK's National Health Service (NHS), has significantly impacted Thakkar's life.

Photo Credit: X/ @NHSEngland

First Indian-Origin Teen to Receive UK's Life-Changing Cancer Therapy

According to NHS England, 16-year-old Thakkar, hailing from Watford near London, became the inaugural child in the UK to undergo a groundbreaking CAR T therapy known as tisagenlecleucel (Kymriah), made possible through the Cancer Drugs Fund (CDF). This milestone coincides with the NHS reaching a significant benchmark of 100,000 patients benefiting from early access to cutting-edge treatments via the CDF, as reported by India Today.

Almost 100,000 cancer patients have benefitted from speedy access to potentially life-extending or life-saving drugs thanks to the NHS Cancer Drugs Fund.

That’s more people like Yuvan who had his life changed through a new cancer treatment. https://t.co/JPwDcMrhAc pic.twitter.com/N0uM6t9kNA

— NHS England (@NHSEngland) March 30, 2024

Thakkar reflects on the immense positive changes brought about by CAR T therapy, acknowledging the exceptional care provided by Great Ormond Street Hospital (GOSH) in London. He expresses appreciation for his restored ability to enjoy activities he loves, such as playing snooker or pool, spending time with loved ones, and embarking on memorable holidays. Thakkar emphasizes the pivotal role of this treatment in his recovery journey, highlighting the invaluable support provided by GOSH in facilitating his remarkable progress.

Thakkar, diagnosed with leukaemia at the age of six, underwent a groundbreaking treatment that alters the body's immune cells to target and destroy cancer cells. His treatment journey commenced in 2019 at the age of 11, following relapses post-chemotherapy and a bone marrow transplant. His mother, Sapna, expressed profound gratitude for the treatment's success, considering it a "second chance" at life for their family, as PTI reports.

She emphasized the pivotal role of the Cancer Drugs Fund (CDF) in providing expedited access to life-saving therapies, without which Thakkar's treatment options may have been limited. Established in July 2016, the CDF facilitates swift access to newly approved cancer treatments endorsed by the National Institute for Health and Care Excellence (NICE), thereby enhancing patient outcomes and extending lives.

Professor Sir Stephen Powis, NHS national medical director, hailed the milestone of treating 100,000 cancer patients in England through the CDF as a testament to the dedication of oncologists nationwide. He underscored the fund's critical role in ensuring timely access to innovative drugs, transforming lives like Thakkar's and offering hope for a healthier future spent with loved ones, as per media reports.

The CDF's extensive scope encompasses various cancer types, ranging from common to rare, underscoring its broad impact on patient care and outcomes. With a substantial budget of GBP 340 million, supplemented by the Innovative Medicines Fund, the CDF continues to play a pivotal role in expediting access to cutting-edge treatments, and fostering breakthroughs in cancer care across England.